Author: Maslow, Joel
Title: GeneOne Life Science Document date: 2018_10_26
ID: w7hf3kji_29
Snippet: Over the next 3 years, GeneOne will move three products (GLS-5300 MERS vaccine, GLS-1027, and quinine) through Phase II development, moving towards Phase IIb/III studies based on results. Additionally, GeneOne’s vaccines against emerging infectious diseases and other targets will continue moving through pre-clinical development and some should mature to the clinical evaluation stage during this timeframe......
Document: Over the next 3 years, GeneOne will move three products (GLS-5300 MERS vaccine, GLS-1027, and quinine) through Phase II development, moving towards Phase IIb/III studies based on results. Additionally, GeneOne’s vaccines against emerging infectious diseases and other targets will continue moving through pre-clinical development and some should mature to the clinical evaluation stage during this timeframe.
Search related documents:
Co phrase search for related documents- clinical evaluation and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- clinical evaluation and MERS vaccine: 1, 2
- clinical evaluation and pre clinical development: 1
- emerge infectious disease and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- iii study and infectious disease: 1, 2, 3, 4
- iii study and phase iib: 1, 2
- infectious disease and MERS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
- infectious disease and pre clinical development: 1, 2, 3, 4, 5, 6
- MERS vaccine and pre clinical development: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date